Evidence map›Paper›PMID 40681935›Full record

ArticleMikrochimica acta2025

Rapid HER2-positive cell detection via high-voltage electroosmotic flow-driven microfluidic SPRi.

Xinmeng Zhang, Yue Jiao, Taikang Yang, Zhourui Xu, Yonghong Shao, Jianxun Hou, Gaixia Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xinmeng ZhangCollege of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen, 518060, China.ORCID 0009-0002-6567-165X
Yue JiaoGuangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518055, China.
Taikang YangShenzhen Testing Center of Medical Devices, Shenzhen Institute for Drug Control, Shenzhen, 518057, China.
Zhourui XuGuangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518055, China.ORCID 0000-0002-2462-9909
Yonghong ShaoCollege of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen, 518060, China.
Jianxun HouShenzhen Testing Center of Medical Devices, Shenzhen Institute for Drug Control, Shenzhen, 518057, China. houhit@szidc.org.cn.
Gaixia XuGuangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518055, China. xugaixia@szu.edu.cn.ORCID 0000-0001-9311-0978

Funding

Basic Research Foundation of Shenzhen JCYJ20220531101814034Medical-Engineering Interdisciplinary Research Foundation of Shenzhen University 2023YG002National Key Research and Development Program of China 2024YFF0726004National Natural Science Foundation of China 62205216Project for Science and Technology Innovation Strategy of Guangdong Province Drug Administration 2023TDB42Project for Science and Technology Innovation Strategy of Guangdong Province Drug Administration 2024TDB44Scientific Instrument Developing Project of Shenzhen University 2023YQ008Shenzhen Medical Research Fund D2401012Start-up Grant from Shenzhen University 868-000001032015
6 · The paper itself

Abstract

The synergy between electroosmotic flow (EOF) and surface plasmon resonance (SPR) offers a transformative approach to overcome diffusion-limited biosensing. However,  existing voltage-driven EOF systems face critical trade-offs between high-voltage requirements and biocompatibility. Here, we present a self-powered electroosmosis-enhanced SPR immunosensor that integrates a triboelectric nanogenerator (TENG) with SPR imaging (SPRi) to achieve ultra-sensitive detection of HER2-positive cancer cells. By leveraging TENG-driven asymmetric alternating electric fields, the developed platform generates electroosmotic vortices that accelerate cellular transport velocity and enhance antigen-antibody binding efficiency, achieving a detection limit of 3 × 10

Indexed as

ElectroosmosisErb-b2 Receptor Tyrosine KinasesMicrofluidic Analytical TechniquesSurface Plasmon ResonanceAntibodies, ImmobilizedCell Line, TumorHumansImmunoassayLimit of DetectionAntibodies, ImmobilizedERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesElectroosmotic flowHuman epidermal growth factor receptor-2Liquid biopsySelf-powered biosensorSurface plasmon resonance imagingTriboelectric nanogenerator

Identifiers

PMID40681935

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.